Myogen, Inc.
Myogen, Inc. was founded as a developer of small molecule therapeutics to treat cardiovascular diseases with two strong drug candidates to treat pulmonary hypertension and resistant hypertension.
Myogen was sold in 1996 to Gilead Sciences Inc. for $2.6 billion cash.